Blutungsfreiheit nach der Umstellung von einer sequenziellen Hormonersatztherapie auf die kontinuierlich kombinierte Gabe von niedrig dosiertem Estradiol und Norethisteronacetat
| Autor: | Viatcheslav Rakov, S. Kretschmar, T. Von Holst |
|---|---|
| Rok vydání: | 2002 |
| Předmět: | |
| Zdroj: | Zentralblatt für Gynäkologie. 124:368-373 |
| ISSN: | 1438-9762 0044-4197 |
| DOI: | 10.1055/s-2002-35547 |
| Popis: | OBJECTIVE Patient's wishes for a hormone replacement therapy (HRT) without withdrawal bleedings are decisive for a good compliance. Systematic experience concerning the bleeding profile when switching from a sequential hormone replacement therapy (s.c.HRT) to a continuous combined hormone replacement therapy (c.c.HRT) is sparse. This non-interfering study is designed to investigate the bleeding profile after such a switch. MATERIAL AND METHODS 1 018 gynaecological centres recruited 3 917 patients pretreated with a s.c.HRT for this study. The switch from the s.c.HRT to the c.c.HRT was performed with a low-dose combination of 1 mg estradiol plus 0.5 mg norethisterone acetate (NETA). The bleeding profile was evaluated after 6 to 9 months of treatment according to the patient's diaries. RESULTS Amenorrhoea was reached in 74.4 % of the enrolled patients after 3 months, in 90.6 % after 6 months, and in 92.1 % after 9 months of treatment. At the time of the switch to the c.c.HRT, already 32.4 % of the women were free of withdrawal bleedings. Parameters like age of the patients, body mass index (BMI), dosage of the estrogen during pretreatment did not influence the results considerably. 92.7 % of the physicians and 92.5 % of the women rated the combined treatment of 1 mg estradiol and 0.5 mg NETA (Activelle) as satisfactory. CONCLUSION The switch from a s.c.HRT to a continuous combined treatment with 1 mg estradiol plus 0.5 mg NETA can be performed without problems, resulting in a high rate of amenorrhoea and a high acceptance of physicians as well as patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|